Clinical Trials on Juvenile Systemic Sclerosis in Netherlands

Total 5422 results

Genzyme, a Sanofi Company

Active, not recruiting

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (LemKids)

Multiple Sclerosis

Portugal, Turkey, Italy, Austria, Belgium, France, Netherlands, Poland, Russian Federation, United Kingdom
GlaxoSmithKline

Completed

Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)

Multiple Sclerosis

Italy, Germany, Spain, United Kingdom, Australia, Netherlands, New Zealand, Russian Federation, France, Canada, Austria, Poland, Finland, Norway
Immunic AG

Active, not recruiting

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis (CALLIPER)

Multiple Sclerosis

United States, Germany, Netherlands, Bulgaria, Serbia, Canada, Czechia, Moldova, Republic of, North Macedonia, Poland, Romania, Ukraine
Pfizer

Completed

Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis (CLIPPER2)

Juvenile Idiopahtic Arthritis

Belgium, France, Serbia, Spain, Germany, Slovakia, Colombia, Hungary, Czechia, Poland, Australia, Italy, Latvia, Lithuania, Mexico, Netherlands, Norway, Russian Federation, Slovenia
EMD Serono Research & Development Institute, Inc.

Completed

CLARITY Extension Study

Relapsing-Remitting Multiple Sclerosis

Croatia, United States, Bulgaria, France, Italy, Russian Federation, Turkey, United Kingdom, Estonia, Germany, Latvia, Lithuania, Poland, Austria, Brazil, Canada, Finland, Portugal, Greece, Serbia, Denmark, Ukraine, Saudi Arabia, Lebanon and more
Hoffmann-La Roche
PPD

Recruiting

A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis (Operetta 2)

Relapsing-Remitting Multiple Sclerosis

United States, Belgium, Canada, Spain, India, Italy, Mexico, Portugal, Argentina, Austria, Brazil, United Kingdom, Germany, Netherlands, Serbia, Australia, Bulgaria, France, Greece, Hungary, Poland, Ukraine, Estonia, Denmark, Croatia, Latvia and more
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo (ARPEGGIO)

Primary Progressive Multiple Sclerosis

United States, Canada, Germany, Italy, Netherlands, Poland, Russian Federation, Spain, Ukraine, United Kingdom
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Multiple Sclerosis Extension Study, Phase II (ATAMS ext)

Relapsing Multiple Sclerosis

Sweden, United States, Czech Republic, Russian Federation, Spain, United Kingdom, Lithuania, Ukraine, Netherlands, Canada, Germany, France, Switzerland, Australia, Belgium, Lebanon, New Caledonia
Ferrer Internacional S.A.
Julius Clinical; Stichting TRICALS Foundation

Active, not recruiting

Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis (ADORE)

Amyotrophic Lateral Sclerosis

Belgium, Netherlands, United Kingdom, Spain, Germany, France, Ireland, Italy, Poland, Portugal, Sweden
Biogen

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, Canada, United Kingdom, Ireland, Netherlands, Switzerland
ZevraDenmark

Terminated

Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

Amyotrophic Lateral Sclerosis

United States, Canada, Netherlands, Belgium, Poland, United Kingdom, France, Germany, Italy, Spain, Sweden
Novartis

Completed

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis

Greece, Russian Federation, Switzerland, Germany, Israel, Ireland, Belgium, Finland, United Kingdom, Netherlands, Canada, Romania, Hungary, Poland, Czech Republic, Australia, Estonia, France, Slovakia, South Africa, Sweden, Turkey
Actelion

Completed

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis

Poland, Ukraine, United Kingdom, United States, Germany, Spain, Bulgaria, Romania, Serbia, Canada, Finland, Sweden, Russian Federation, Hungary, Czechia, Netherlands, Israel, Switzerland, Austria, France
Biogen

Completed

Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. (MOBILE)

Multiple Sclerosis

Sweden, United Kingdom, Netherlands, Belgium, Canada, Italy
Bayer

Completed

Physical Activity and Fatigue in Early Multiple Sclerosis (MS) (BEGIN)

Multiple Sclerosis

Switzerland, France, Germany, Indonesia, Korea, Republic of, Spain, Sweden, Thailand, Taiwan, Australia, Austria, Colombia, Czech Republic, Italy, Jordan, Kazakhstan, Lebanon, Mexico, Slovenia, United Kingdom, Bahrain, Egypt, United... and more
Biogen

Active, not recruiting

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation (ALSpire)

Amyotrophic Lateral Sclerosis

United States, Netherlands, Italy, Canada
Macquarie University, Australia
King's College London; Stichting TRICALS Foundation

Recruiting

Triumeq in Amyotrophic Lateral Sclerosis (LIGHTHOUSE II)

Amyotrophic Lateral Sclerosis

Spain, Australia, United Kingdom, New Zealand, Netherlands, Ireland, Slovenia, Sweden
EMD Serono

Terminated

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) (ATAMS)

Relapsing Multiple Sclerosis

United States, Sweden, Australia, Czech Republic, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Ukraine, Netherlands, Canada, France, Austria, Lebanon, Switzerland, Belgium
Biogen

Completed

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis (DEFINE)

Relapsing-Remitting Multiple Sclerosis

Croatia, United States, Czech Republic, France, Italy, Mexico, South Africa, United Kingdom, Germany, Poland, Romania, Ukraine, Netherlands, Austria, Canada, Israel, New Zealand, Slovakia, Greece, Serbia, India, Belgium, Switzerland, ... and more
Biogen

Completed

Efficacy and Safety of BG00012 in MS

Multiple Sclerosis

Russian Federation, Sweden, Germany, Poland, Hungary, United Kingdom, Netherlands, Switzerland, Turkey, Czechia
Biogen

Completed

Methodology Study of Novel Outcome Measures to Assess Progression of ALS

Amyotrophic Lateral Sclerosis

Canada, United States, Belgium, Germany, Switzerland, Ireland, Netherlands, France, United Kingdom
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United Kingdom, United States, Canada, Belgium, Czech Republic, France, Germany, Netherlands
Biogen

Completed

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)

Relapsing-Remitting Multiple Sclerosis

United States, France, Germany, Spain, Belgium, Czechia, Switzerland, United Kingdom, Austria, New Zealand, Australia, South Africa, Ukraine, Italy, Slovakia, Greece, Poland, Israel, Netherlands, Bulgaria, Serbia, India, Romania, Estonia and more
Genzyme, a Sanofi Company

Completed

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 (TOPAZ)

Relapsing Remitting Multiple Sclerosis

United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, Denmark, Germany, Israel, Italy, Mexico, Netherlands, Poland, Russian Federation, Spain, Sweden, Ukraine, United Kingdom
Humanitas Mirasole SpA
KU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaborators

Recruiting

Open Label Extension of TUDCA-ALS Study (TUDCA-ALS OLE)

Amyotrophic Lateral Sclerosis

Germany, France, Netherlands, Italy, United Kingdom, Belgium, Ireland
Actelion

Completed

Digital Ulceration (CAP)

Systemic Sclerosis | Digital Ulcers

Belgium, Spain, United Kingdom, Germany, Italy, Portugal, France, Israel, Netherlands, Turkey, Austria, Switzerland, Greece, Czech Republic, Norway
Celgene

Completed

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Leukemia, Myelomonocytic, Juvenile | Myelodysplastic Syndrome

Spain, Germany, Italy, United Kingdom, Belgium, France, Denmark, Netherlands, Sweden, Switzerland, Austria, Czechia, Ireland
Actelion

Completed

Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Switzerland, Ukraine, United Kingdom
Corcept Therapeutics

Active, not recruiting

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (DAZALS)

Amyotrophic Lateral Sclerosis

United States, Belgium, Canada, France, Germany, Ireland, Netherlands, Poland, Spain, United Kingdom
ZevraDenmark

Completed

Arimoclomol in Amyotropic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

Canada, United States, Belgium, Netherlands, Poland, United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland
Novartis

Completed

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (FREEDOMS)

Relapsing-remitting Multiple Sclerosis

Canada, Australia, Israel, Belgium, Czech Republic, Finland, France, Germany, Greece, Lithuania, Netherlands, Poland, Russian Federation, Slovakia, South Africa, Sweden, Switzerland, Turkey, United Kingdom
Diamyd Medical AB

Completed

Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes

Glucose Metabolism Disorders | Immune System Diseases | Autoimmune Diseases | Diabetes Mellitus | Endocrine System Diseases | Diabetes Mellitus, Type 1 | Metabolic Disease | Vitamin D | Autoimmune Diabetes | Physiological Effects of Drugs | Juvenile Diabetes | Insulin Dependent Diabetes

Czechia, Netherlands, Spain, Sweden
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (CONSONANCE)

Progressive Multiple Sclerosis (PMS)

United States, Canada, Brazil, France, Netherlands, Ireland, Germany, Italy, Poland, Russian Federation, Spain, Colombia, Morocco, Hungary, Denmark, Lebanon, Mexico, Costa Rica, Bosnia and Herzegovina, Czechia, Egypt, Guatemala, Panama and more
Biogen

Terminated

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States, Canada, United Kingdom, Netherlands, Switzerland
Biogen

Completed

Tysabri Observational Program (TOP)

Relapsing-Remitting Multiple Sclerosis

Belgium, Germany, Italy, Norway, France, Mexico, Australia, Spain, Portugal, Greece, Netherlands, United Kingdom, Czechia, Slovakia, Finland, Canada, Argentina, Brazil
Amylyx Pharmaceuticals Inc.

Enrolling by invitation

Extension Study Evaluating The Safety And Tolerability of AMX0035

Amyotrophic Lateral Sclerosis

Belgium, Spain, Netherlands, United Kingdom, Sweden, France, Germany, Ireland, Italy, Poland, Portugal
Sanofi

Completed

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis (TEMSO)

Multiple Sclerosis

Ukraine, Russian Federation, Estonia, Czech Republic, Denmark, Finland, France, Turkey, United Kingdom, United States, Portugal, Austria, Canada, Chile, Germany, Italy, Netherlands, Norway, Poland, Sweden, Switzerland
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc) (focuSSced)

Systemic Sclerosis

Belgium, United Kingdom, Mexico, Poland, United States, Japan, Argentina, Netherlands, Canada, France, Lithuania, Germany, Spain, Bulgaria, Denmark, Greece, Hungary, Italy, Portugal, Puerto Rico, Romania, Switzerland
Novartis Pharmaceuticals

Terminated

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. (INFORMS)

Primary Progressive Multiple Sclerosis

United States, Belgium, Poland, Germany, Hungary, Turkey, Spain, Australia, Canada, Czechia, Switzerland, United Kingdom, Netherlands, France, Italy, Denmark, Finland, Sweden
GlaxoSmithKline

Completed

Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, France, Australia, Canada, Belgium, Germany, Korea, Republic of, Japan, Netherlands, Italy, United Kingdom
Novartis Pharmaceuticals

Completed

Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis (OCTIMS)

Multiple Sclerosis | RRMS

Spain, Czechia, Germany, Australia, Italy, Switzerland, Denmark, United States, United Kingdom, Canada, Netherlands, Poland
Biogen

Completed

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Multiple Sclerosis, Relapsing-Remitting

United States, Spain, Canada, Australia, Germany, Italy, United Kingdom, Belgium, Netherlands, France, Israel
Biogen

Terminated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)

Secondary Progressive Multiple Sclerosis

United States, Finland, Italy, Spain, Canada, France, Israel, Sweden, Netherlands, Belgium, Poland, United Kingdom, Czechia, Denmark, Russian Federation, Germany, Ireland
Cytokinetics

Completed

A Study for Patients Who Completed VITALITY-ALS (CY 4031) (VIGOR-ALS)

Amyotrophic Lateral Sclerosis (ALS)

United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
Hoffmann-La Roche

Active, not recruiting

Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis (MuSicalE)

Multiple Sclerosis

Belgium, United Kingdom, Netherlands, Serbia, Poland, Slovakia, Bulgaria, Turkey, Brazil, Italy, Russian Federation, Spain, Austria, Colombia, Romania, Kuwait, Chile, Dominican Republic, Egypt, Montenegro, Panama, Paraguay, Portugal, ... and more
Biogen

Completed

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (ATTAIN)

Relapsing Multiple Sclerosis

United States, Croatia, Russian Federation, India, Spain, New Zealand, Canada, Belgium, Netherlands, Bulgaria, Serbia, Greece, Ukraine, Mexico, Georgia, Colombia, Germany, Poland, United Kingdom, Czech Republic, France, Chile, Romania, Eston... and more
Novartis

Completed

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

Relapsing Multiple Sclerosis

Germany, Italy, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, Greece, Hungary, Ireland, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Spain, Sweden, Switzerland, Turkey, United Kingdom
Apellis Pharmaceuticals, Inc.

Terminated

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

United States, Netherlands, Spain, Germany, Japan, Australia, France, Poland, Ukraine, Belgium, Czechia, Ireland, Italy, United Kingdom
Ionis Pharmaceuticals, Inc.

Recruiting

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

Amyotrophic Lateral Sclerosis

United States, Germany, Netherlands, Spain, Korea, Republic of, Canada, Switzerland, Belgium, Italy, United Kingdom, Ireland, Sweden, Taiwan, Brazil
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Multiple Sclerosis, Relapsing-Remitting

Belgium, United Kingdom, Australia, Netherlands, Ireland, Norway, Turkey, Estonia, Denmark, Germany, Italy, Spain, Switzerland, France, Finland, Sweden, Czechia

Clinical Trials on Juvenile Systemic Sclerosis in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations